B
LGND icon

Bailard’s Ligand Pharmaceuticals LGND Stock Holding History

Bailard’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$443K Hold
1,400
– – 0.01% 534
2026
Q1 		$280K Hold
1,400
– – 0.01% 634
2025
Q4 		$265K Hold
1,400
– – 0.01% 628
2025
Q3 		$248K Buy
+1,400
New +$208K 0.01% 685
2013
Q3 		– Sell
-104,195
Closed -$2.43M – 227
2013
Q2 		$2.43M Buy
+104,195
New +$1.87M 0.44% 44

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bailard's LGND Position: Q2 2026 in Review

Bailard held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 1,400 shares worth $443K. The position accounts for 0.01% of the portfolio, ranked #534.

Bailard first reported a position in LGND in Q2 2013 and has held it in 5 quarters since. The position peaked at $2.43M in Q2 2013. 415 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Bailard held 1,400 shares of Ligand Pharmaceuticals worth $443K as of Q2 2026.
  • Bailard left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
  • Ligand Pharmaceuticals made up 0.01% of Bailard's portfolio in Q2 2026, its #534 holding.
  • Bailard first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 5 quarters since.
  • Bailard's Ligand Pharmaceuticals position peaked at $2.43M in Q2 2013.
  • 415 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.